NeuroTherapia, Inc.

NeuroTherapia, Inc.
NeuroTherpia, Inc., founded in 2015 by Drs. Mohamed Naguib and Joseph Foss, is developing new therapies for diseases with an underlying component of neuroinflammation. Initial research has led to the development of our lead compound NTRX-07. NTRX-07 (previously known as MDA7) has been shown to decrease activation of microglial cells in the brain. Decreasing activation of these cells leads to decreased inflammation and decreased injury to surrounding nerve cells. Decreasing this inflammation can treat and even prevent the development of neuropathic pain in settings of nerve injury or chemotherapy. Recent work has shown that blocking this inflammation is also important in reversing the effects seen in Alzheimer's disease. We are currently doing preclinical safety studies and are initiating Phase I clinical trials of NTRX-07 in humans in 2019.
Location: United States, Ohio, Cleveland
Member count: 11-50
Total raised: $8.8M
Founded date: 2015

Investors 1

Funding Rounds 1

DateSeriesAmountInvestorsDeal News
22.09.2020Series A$

Mentions in press and media 4

25.09.2020NeuroThera...NeuroTherapia, Inc., a
22.09.2020NeuroThera... CLEVELAND, Sept. 22, 2020 /P...--prnewswire...
28.12.2016Startup Sp...The road to find an effective ...--statnews.c...